H3N2 News and Research

RSS
Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.
Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

Study shows seasonal flu vaccines may protect individuals against many different viruses

Study shows seasonal flu vaccines may protect individuals against many different viruses

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

CDC urges all adults to get flu vaccination

CDC urges all adults to get flu vaccination

Getting flu shot every autumn can lead to better health

Getting flu shot every autumn can lead to better health

Avian influenza A H3N8 virus poses threat to humans

Avian influenza A H3N8 virus poses threat to humans

CDC report reveals that younger age group is mostly hit by flu this season

CDC report reveals that younger age group is mostly hit by flu this season

Researchers show for first time how influenza A viruses infect respiratory cells

Researchers show for first time how influenza A viruses infect respiratory cells

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

Emerging H7N9 virus has potential to cause a pandemic

Emerging H7N9 virus has potential to cause a pandemic

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Seattle researchers map critical molecules that regulate inflammation during flu infection

Seattle researchers map critical molecules that regulate inflammation during flu infection

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides files Orphan Drug application with FDA for DengueCide

iBio announces production of vaccine candidate for new H7N9 influenza virus

iBio announces production of vaccine candidate for new H7N9 influenza virus

New MIT study reveals that H3N2 strains could pose a risk to humans

New MIT study reveals that H3N2 strains could pose a risk to humans

SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.